INTRODUCTION
Hepatocyte growth factor (HGF) is a well known growth factor that has been implicated to be involved in the mitogenic process, cell motility, angiogenesis and epithelial morphogenesis, while playing a pleiotropic role in other biological processes such as normal development, wound healing, and carcinogenesis [1] [2] [3] [4] [5] . c-Met receptor (170 kD) is a growth factor receptor, formed by two polypeptide chains of α-subunit (50 kD) and β-subunit (145 kD) linked by disulfide bonds. These chains make up an extracellular ligand-binding domain, a hydrophobic transmembrane segment and an intracellular tyrosine kinase domain 5 . Generally, it has been understood that c-Met is located in cytoplasmic portion of the cell. But, in recent studies, it was reported that c-Met can be located or translocated to the nucleus in some cancer cells 6, 7 . C-Met was initially identified as the protein product of a transforming oncogene 8, 9 . C-Met pathway is activated by HGF, which then increases cellular mobilization and invasiveness 4, 10 . There are some reports that show over-expression of c-Met in a number of human cancers, including thyroid, pancreas, stomach, prostate, colon, ovary, breast, kidney, liver and endometrial cancers [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Some cancers, such as gastric cancers and thyroid cancers, have been shown to have a relationship between c-Met expression with tumor stage and poor prognosis 12, 13 . One study reported that metastatic melanomas had an increased level of c-Met expression among melanocytic lineage lesions 13 . In this study, we examined c-Met location and c-Met expression in human malignant skin cancers. 
MATERIALS AND METHODS

Tissue samples
Cell culture
The human malignant melanoma cell line G361 and human squamous cell carcinoma cell lines A431 were cultured in DMEM, 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin at 37 o C, 5% CO2.
Subcellular fractionation
Cytoplasmic and nuclear extracts were prepared according to the instructions of the NE-PER Ⓡ nuclear and cytoplasmic extraction kit (Pierce, Rockford, IL, USA). The fractions were then stored at −80 o C and used for Western blot analysis.
Immunoprecipitation and Western blot analysis
1) Immunoprecipitation
For immunoprecipitation, 500μl of cell extract (∼1.0 mg/ml protein) was incubated with 1μl of affinity purified rabbit polyclonal c-Met antibody (SC-161; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 10 mg/ml, at 4 o C overnight, followed by the addition of 30μl of Protein A/G PLUS-Agarose (SC-2003; Santa Cruz Biotechnology) for another 3 hr with shaking. The immunoprecipitates were collected by centrifugation, washed three times with 0.5 M LiCl, once with 1 ml of solution B (20 mM Tris-HCI at pH 7.0, 0.5 mM dithiothreitol, 1 mM phenylmethanesulfonylfluoride 1 mM benzamidine, and 0.5 mg/ml aprotinin).
2) Western blot analysis
Proteins from the subcellular fraction and immunoprecipitates were separated on NuPAGE 4∼12% bis-Tris polyacrylamide gels (Invitrogen, Camarillo, CA, USA) and then electrophoretically transferred to Immuno-Blot PVDF membranes. The membranes were then incubated for 1 hr at room temperature, with a 1:500 dilution of rabbit anti-c-Met antibody (Santa Cruz Biotechnology). Next, horseradish peroxidase-conjugated secondary antibody (Cell signaling Technologies, Beverly, MA, USA) was applied at a dilution of 1:5,000. Anti-β-actin antibody was used as a loading control and the signal was visualized using an ECL detection kit (Amersham Biosciences, Amersham, Buckinghamshire, UK).
Immunohistochemical staining
For immunohistochemical analysis, Parraffin sections (4μm) were prepared and staining was performed by the ABC method. In brief, slides were deparaffinized in xylene and rehydrated with ethanol. The endogenous peroxidase activity was inhibited by immersion of the slides in 3% H2O2/methanol. Antigen retrieval was performed in a microwave oven for 15 min with 10 mM citrate buffer (pH 6.0). Pre-incubation took place with a blocking solution for 30 min, to avoid unspecific binding. The sections were then incubated over night at 4 o C with the primary c-Met-specific polyclonal antibody (SC-161; Santa Cruz Biotechnology, 1:100). The slides were consecutively incubated with biotinylated secondary antibody for 30 min and then for 30 min with streptavidin-peroxidase. The visualization of the immunoreaction was performed with 3,3'-Diaminobenzidine (DBC500; ScyTek, Logan, UT, USA). Negative controls were performed as previously described, substituting the primary antibody with phosphate buffered saline.
Assessment of immunohistochemical staining
In immunohistochemical evaluation, the histochemical score (HSCORE) was used for comparison and standardization [23] [24] [25] . The HSCORE of c-Met was determined by two sets of independent investigators. In c-Met stain, cells with brown cytoplasm under an optical microscope meant positive. HSCORE was calculated using the following equation: HSCORE ΣPi(i＋1), where i is the intensity of staining with a value of 0, 1 or 2 (0, weak staining; 1, moderate staining or 2, strong staining) and Pi is the percentage of stained tumor cells varying from 0% to 100% (0.0∼1.00). HSCOREs ranged from a minimum of zero in cases with no staining to a maximum of 3.0 in cases in which all the tumor cells were stained with maximal intensity. The percentage of stained tumor cells were calculated by counting positively stained cells among 500 tumor cells, using 10×10 grid in 400 magnified view.
Statistical analysis
The data of the immunohistochemical study were analyzed using the nonparametric Kruskal Wallis test. p＜0.05 was considered statistically significant. 
RESULTS
Western blot analysis
The results of the Western blot analysis showed that c-Met was expressed in both cell lines-G361 cells and A431 cells. The c-Met was located within the cytoplasmic fraction of both cells (Fig. 1) .
Immunohistochemical examination
The staining pattern of c-Met in MM, SCC and BCC could be observed (Fig. 2) . Immunohistochemical study further supported the Western blot analysis that c-Met expression was increased in MM and SCC ( showed that c-Met was strongly expressed in MMs, while it was moderately expressed in SCCs and slightly expressed in BCCs, thereby revealing statistically significant differences among these cancers (p＜0.001). However, in normal human skin tissues, c-Met was not well-expressed (Fig. 3) . MMs have stronger positive responses than do other cancers and normal skin tissues. Indeed, deeper invasive melanoma tissues are observed to have more increased positive responses to the immunohistochemicals among theses MM tissues (Fig. 4) .
DISCUSSION
There are now over 75 known human receptor tyrosine kinases (RTK), and many of them are reported to induce alterations in signal transduction molecular pathways 4, 10, 26 . They are known as proto-oncogenes involved in oncogenesis and tumor progression mechanisms. Examples of such RTK proto-oncogenes are EGF, c-kit, PDGF, Flt3 and c-Met 10, 26 . c-Met was originally identified as an activated oncogene protein involved in a chromosomal translocation in a human osteogenic sarcoma cell line treated with N-methyl-N-nitro-N-nitrosoguanidine 11 . Activation of HGF/c-Met signal pathways has been known to promote cell motility, morphogenesis, wound healing and tissue regeneration. However, c-Met is also expressed in a variety of malignant cells. In an animal model study, the over expression of wild-type Met among hepatocytes was identified to be sufficient enough to cause hepatocellular carcinomas and c-Met mutations also have been reported in various other cancers 27, 28 . Germ line missense mutations of c-Met, found in hereditary papillary renal carcinomas, provides compelling evidence that c-Met has a direct role in human cancers. Met-activating mutations are also found in gastric cancer and hepatocellular carcinomas 26, 28 . In addition to these cancers, there are many reports identifying increased c-Met expression in other cancers such as colon cancers, dermatofibroma sarcoma protuberans, breast cancers, prostate cancers, endometrial cancers, ovarian cancers, lung cancers and head and neck cancers.
Studies surrounding the expression of c-Met in skin cancers are rare. There is one paper which observes the expression of c-Met in melanomas and melanocytic lineages. In a study researching the expression of c-Met in human melanocytic lesions, c-Met receptor expression was detected not in benign melanocytic lesions but in melanomas, especially metastatic melanomas 13 . It has been suggested that c-Met expression may be correlated with metastatic progression. In a study observing the distribution of HGF in human tissues, HGF was observed not only in active mitochemical cell populations, but also in mitotically quiescent and non-dividing cells. Indeed, almost all growth factors are found at low concentrations in various cells, but high affinity binding between growth factors and its receptors are required to induce the specific signals 29 . This implies that c-Met, the HGF receptor, is important to the signal transduction process. It has been well-known that c-Met is located in the cytoplasm, however, interestingly, in recent studies it was found that c-Met can be translocated to the nucleus either by HGF stimulation or without HGF 6 . c-Met cytoplasmic fragments were present in the nuclei especially in MDA-MB231 breast carcinoma cells 6 . But, in other studies with SkHep1 cells, c-Met was found only in the cytoplasmic portion 7 .
To identify c-Met in malignant skin cancer cells, we separated the cytoplasmic portion and nucleus portion of G361 cells and A431 cells; as a result, c-Met was found to be expressed in the cytoplasm just like in SkHep1 cells. In order to identify the role of c-Met in skin cancers, we examined malignant skin cancers, including BCCs, SCCs and MMs. Our results showed that, based on immunohistochemical stains, all skin cancers display increased c-Met expression. MMs have a stronger positive response than other cancers. Protein expressions corresponded to our results. Immunohistochemically, deeper MMs were observed to express c-Met more strongly than superficial ones. C-Met is thought to be related to the malignancy potential. MM is characterized as one of the most invasive cancers. In a prostate cancer study, mitogenic activity of HGF increased in a dose dependent manner and c-Met expression was increased according to the HGF, suggesting that a complex of autocrine, paracrine and endocrine trophic or mitogenic pathways may be involved in the progression of cancer invasion 30 . These results imply that c-Met may be implicated, in part, in tumor progression (invasion or metastasis) and that the difference of HGF receptors on tumor cells may be the defining feature of malignancy in skin cancers. In addition, there have been other examples postulating that HGF secreted by stromal cells could facilitate invasion, according to c-Met expression in various c-Met over-expressing cancers, including gastric adenocarcinoma, colorectal carcinoma, thyroid cancer, head and neck cancer and breast cancers [31] [32] [33] [34] . There are now substantial hypotheses that RTK such as c-Met may play a role in tumorigenesis and tumor progression, with its anti-apoptotic and pro-invasive activities helping to overcome the selective barriers to cancer progression 17 . Indeed, the HGF/c-Met system functions in a pro-angiogenic role; these activities have been known to induce tumor invasion and metastasis. This is supported by our study, where deeper MMs displayed higher expressions of c-Met. Therefore, c-Met is thought to be closely involved in skin cancer development, especially MMs. Malignancy and prognosis can be presumed according to the level of c-Met expression in MMs.
